Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and expansion of manufacturing capabilities.
ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Study finds restrictive clinical trial criteria excludes Lyme disease patients
Percheron plans to broaden pipeline following avicursen disappointment
Xgene’s non-opioid analgesic reduces pain in Phase IIb trial
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst